immunotherapy - search results

In this Inside Precision Medicine webinar, our distinguished guest speaker, Dr. Scott Tomlins, will describe the development, validation, and clinical utility of a new pan-tumor predictive biomarker for immunotherapy benefit: Immunotherapy Response Score^™ (IRS).

Using a chemical blocker stops CD8+ T cells from migrating out of skin cancer cells. Together with immunotherapy, this new approach could boost the efficacy of immunotherapy.

CD5+ cells could be an important marker for response to immunotherapy for melanoma and other cancers, according to new research from the Washington University School of Medicine. 

Bacteria naturally found in the lungs help create an environment that suppresses T-cell activation in the lymph nodes near the lungs—a finding that could explain why immunotherapy for lung cancer often fails.

New evidence from researchers at the Johns Hopkins Kimmel Cancer Center has found that a subset of mutations within the TMB—defined at “persistent mutations"—are less likely than others to be edited out, making them always visible to the immune system which results in them being more likely to respond to immunotherapies.

L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase TILs, promote antitumor immunity, and improve the efficacy of immunotherapy.

Using immune checkpoint inhibitors prior to surgery of patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) is an effective approach to treating the disease

Gilead Sciences and Jounce Therapeutics announced late Tuesday amendments to the existing terms and licensing agreements for GS-1811 (previously called JTX-1811), a potential first-in-class anti-CCR8 antibody in development as a potential treatment against solid tumors.

Tired T cells not only lose their own ability to fight cancer; they also influence surrounding cells to suppress an immune response.

The research will be led by Prof. Jonas Fuxe, and will characterize the molecular targets of Qu's Site Specific Immunomodulator (SSI) therapy at the tissue level that lead to resolution of disease.